New Delhi, April 8 Biocon Ltd announced on Wednesday that its subsidiary, Biocon Pharma Ltd, has received approval from the US health regulator for its genetically engineered version of dapagliflozin tablets, indicated for reducing blood sugar levels in adults with type 2 diabetes mellitus.The...
biocon ltd
biosimilarinsulin
blood sugar control
cardiovascular disease
dapagliflozin
diabetes mellitus
drug approval
generic medicine
glp-1 peptides
heart failure
oral solid dosage formulations
pharmaceutical manufacturing
tablet
type 2 diabetes
us food and drug administration (usfda)